These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23030220)

  • 21. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
    Jahanzeb M
    Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer.
    Nakamura S; Ando M; Masuda N; Aogi K; Ino H; Iwata H; Tokuda Y; Yamamoto N; Kasai H; Takeuchi M; Tsuda H; Akiyama F; Kurosumi M; Fujiwara Y
    Clin Breast Cancer; 2012 Feb; 12(1):49-56. PubMed ID: 22154118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care.
    Brufsky A
    Am J Clin Oncol; 2010 Apr; 33(2):186-95. PubMed ID: 19675448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER2-positive early breast cancer and trastuzumab: a surgeon's perspective.
    Kulkarni S; Hicks DG
    Ann Surg Oncol; 2008 Jun; 15(6):1677-88. PubMed ID: 18398661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
    Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.
    Valachis A; Nearchou A; Lind P; Mauri D
    Breast Cancer Res Treat; 2012 Oct; 135(3):655-62. PubMed ID: 22875745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant systemic therapies in breast cancer.
    Hernandez-Aya LF; Gonzalez-Angulo AM
    Surg Clin North Am; 2013 Apr; 93(2):473-91. PubMed ID: 23464697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
    Sabatier R; Gonçalves A
    Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].
    Sawaki M; Tokudome N; Mizuno T; Nakayama T; Taira N; Bando H; Murakami S; Yamamoto Y; Kashiwaba M; Iwata H; Uemura Y; Ohashi Y
    Jpn J Clin Oncol; 2011 May; 41(5):709-12. PubMed ID: 21355003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer.
    Horiguchi J; Oyama T; Koibuchi Y; Yokoe T; Takata D; Ikeda F; Nagaoka H; Rokutanda N; Nagaoka R; Ishikawa Y; Odawara H; Kikuchi M; Sato A; Iino Y; Takeyoshi I
    Anticancer Res; 2009 Feb; 29(2):517-24. PubMed ID: 19331197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.
    Abair T; O'Shaughnessy J
    Clin Breast Cancer; 2011 Feb; 11(1):15-9. PubMed ID: 21989832
    [No Abstract]   [Full Text] [Related]  

  • 33. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast cancer: review of platinum-based cooperative group trials.
    Pegram M
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S2-9. PubMed ID: 19780241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
    Zhang B; Hurvitz S
    Clin Adv Hematol Oncol; 2016 Jul; 14(7):520-30. PubMed ID: 27379947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Rationale for Herceptin in the clinical use].
    Ebi H; Sasaki Y
    Nihon Rinsho; 2002 Mar; 60(3):463-7. PubMed ID: 11904959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
    Guarneri V; Frassoldati A; Bruzzi P; D'Amico R; Belfiglio M; Molino A; Bertetto O; Cascinu S; Cognetti F; Di Leo A; Pronzato P; Crinó L; Agostara B; Conte P
    Clin Breast Cancer; 2008 Oct; 8(5):453-6. PubMed ID: 18952561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
    Candon D; Healy J; Crown J
    Acta Oncol; 2014 Feb; 53(2):201-8. PubMed ID: 24125103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    J Clin Oncol; 2007 Apr; 25(10):1232-8. PubMed ID: 17296975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
    Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.